Aug 25 (Reuters) - Thoma Bravo will acquire Verint Systems (VRNT.O), opens new tab in a $2 billion deal, including debt, the customer engagement platform said on Monday, marking the latest software ...

(Reuters) -Thoma Bravo will acquire Verint Systems in a $2 billion deal, including debt, the customer engagement platform said on Monday, marking the latest software buyout as private equity firms ...

Investing.com-- Thoma Bravo is close to a deal to buy call center software maker Verint Systems Inc (NASDAQ: VRNT), Bloomberg reported on Friday, in a deal that could value the latter at $2 billion ...

Fast food companies have been experimenting with integrating artificial intelligence into their restaurants, from Flippy the burger-flipping robot at White Castle to dynamic pricing at Wendy's. One ...

Investing.com -- Hexagon AB (ST:HEXAb) shares rose more than 6% on Friday after Cadence Design Systems (NASDAQ:CDNS) announced a €2.7 billion deal to acquire Hexagon’s Design and Engineering business, ...

MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp(a) inhibitor from China's Jiangsu Hengrui Pharma for $200 million upfront. The deal gives MSD exclusive rights to the ...

If you haven't already, you can now download the new iOS 26 on your iPhone. Once you do, get ready to see a slew of changes, including a new clear design called Liquid Glass. The translucent look can ...

Commenters are calling out Will Smith for using AI in a concert video. The video, posted to YouTube on Aug. 12, features the actor and rapper performing on stage with a montage of his audiences. The ...

Take-Two Interactive Software, Inc. engages in the development, publishing, and marketing of interactive software games. Its products are designed for console systems, handheld gaming systems, and ...

Whether you're creating short videos for social media or working on a feature-length film, the right editing software is essential. We've tested and rated the best video editing software for all types ...

Kelun-Biotech has become the second drugmaker to bring a TROP2-directed antibody-drug conjugate to regulatory approval, getting a green light in China for sacituzumab tirumotecan (sac-TMT). The ...